Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Clinical trial NCT04008706 · COMPLETED

Trial details

NCT number: NCT04008706
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2019-09-17
Primary completion: 2025-11-04
Enrollment: 552

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.